Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.23
-2.2%
$2.21
$1.63
$4.66
$12.27M0.81275,641 shs58,760 shs
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$0.67
-2.7%
$0.77
$0.58
$5.54
$26.64M-0.78314,230 shs411,673 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.18
+2.2%
$10.70
$4.11
$28.68
$67.02M2.97175,242 shs26,851 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.72
-0.4%
$0.76
$0.62
$1.70
$37.39M-0.151.44 million shs148,396 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%-6.69%+5.19%+16.15%-28.30%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
0.00%+6.69%-6.49%-43.58%-87.54%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
0.00%-3.51%-18.17%+38.69%+43,779.31%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
0.00%-1.65%+9.29%-3.94%-26.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCardia, Inc. stock logo
BCDA
BioCardia
3.0179 of 5 stars
3.83.00.00.01.72.50.6
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.2513 of 5 stars
3.65.00.00.01.12.50.6
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
2.8353 of 5 stars
3.55.00.00.00.61.70.6
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
2.1341 of 5 stars
3.52.00.00.00.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,021.08% Upside
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
3.20
Buy$13.001,836.25% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$61.00499.21% Upside
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
3.00
Buy$4.00454.02% Upside

Current Analyst Ratings Breakdown

Latest BCDA, XLO, FBLG, and FBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$61.00
6/17/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/15/2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K4,091.31N/AN/A$0.18 per share12.39
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.08 per shareN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$6.34M5.90N/AN/A$0.40 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-149.15%-114.25%8/13/2025 (Estimated)
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$58.24M-$0.84N/AN/AN/A-585.54%-262.69%-64.01%8/14/2025 (Estimated)

Latest BCDA, XLO, FBLG, and FBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$0.10N/AN/AN/AN/AN/A
8/13/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21N/AN/AN/AN/AN/A
8/6/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.11N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$0.89-$1.37-$0.48-$1.37N/AN/A
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/13/2025Q1 2025
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.10-$0.14-$0.04-$0.14N/AN/A
5/13/2025Q1 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
0.36
0.36
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
1.14
1.14
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
5.22
5.22
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/A
1.96
1.96

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
54.29%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
20.00%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.50 million4.40 millionOptionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1039.68 million31.75 millionN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
56.58 million6.20 millionOptionable
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
7051.78 million49.09 millionNot Optionable

Recent News About These Companies

Xilio Therapeutics Announces Proposed Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.23 -0.05 (-2.19%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.14 -0.09 (-3.81%)
As of 07/18/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$0.67 -0.02 (-2.70%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.67 0.00 (-0.21%)
As of 07/18/2025 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$10.18 +0.22 (+2.21%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$10.25 +0.07 (+0.70%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Xilio Therapeutics stock logo

Xilio Therapeutics NASDAQ:XLO

$0.72 0.00 (-0.41%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.97%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.